AtrialFibrillationAblation.com
Pulsed field ablation for atrial fibrillation: what is different, safer, faster, and still uncertain.
PFA uses very short high-voltage electrical pulses rather than heat or freezing. The best current evidence shows similar 12-month rhythm outcomes to established thermal ablation, shorter procedures in many workflows, and a safety profile that appears especially strong for esophageal injury, pulmonary vein stenosis, and persistent phrenic nerve palsy.
What the evidence says
The short version: safer-looking tissue selectivity, similar first-year rhythm control, still early for long-term durability.
ADVENT: FARAPULSE vs RF or cryoballoon
In symptomatic drug-refractory paroxysmal AF, PFA was noninferior to thermal ablation for 12-month composite efficacy and safety. The trial did not prove superiority for recurrence.
- Patients
- 607 randomized
- Efficacy
- 73.3% PFA vs 71.3% thermal
- Safety
- 2.1% PFA vs 1.5% thermal serious events
PULSED AF: Medtronic PulseSelect
Prospective, multicenter, nonrandomized data showed low primary safety events and 12-month effectiveness consistent with established ablation technologies.
- Patients
- 300 pivotal
- Effectiveness
- 66.2% paroxysmal, 55.1% persistent
- Safety
- 0.7% primary safety events
MANIFEST-17K: pentaspline PFA safety
The largest published post-approval safety registry for FARAPULSE showed low major complications and no reported esophageal fistula, pulmonary vein stenosis, or persistent phrenic palsy.
- Patients
- 17,642
- Major complications
- 0.98%
- Signals
- Coronary spasm 0.14%, dialysis-level hemolysis 0.03%
AdmIRE: J&J / Biosense Webster VARIPULSE
Integrated with CARTO mapping, the variable-loop system achieved short PVI times and 12-month effectiveness in paroxysmal AF, with pericardial tamponade the most common primary adverse event.
- Patients
- 277 pivotal
- Effectiveness
- 74.6% composite, 75.4% freedom from AF/AT/AFL recurrence
- Safety
- 2.9% primary adverse events
Compare and contrast
PFA versus older thermal ablation
Thermal ablation remains effective and widely used. PFA's advantage is not that it magically prevents recurrence; it is that it can create myocardial lesions without relying on heat or cold, which appears to reduce several feared off-target injuries.
| Dimension | Radiofrequency ablation | Cryoballoon ablation | Pulsed field ablation |
|---|---|---|---|
| Energy | Heat from RF current, point-by-point or linear lesions. | Freezing via balloon positioned at pulmonary vein ostia. | Nonthermal irreversible electroporation from brief electric fields. |
| Procedure duration | Often longer when point-by-point mapping is used; many centers quote about 2 hours or more. | Often faster than RF for PVI but workflow depends on anatomy and operator. | Commonly shorter in studies. Meta-analysis reported about 44 minutes shorter than thermal approaches; PULSED AF reported most procedures under 1 hour. |
| Safety pattern | Low overall major complication rate in expert hands, but collateral thermal injury can include esophageal injury, PV stenosis, phrenic nerve injury, tamponade, vascular injury, and stroke. | Low overall major complication rate; phrenic nerve palsy is a known issue and esophageal injury is rare but possible. | Large registry signal: no reported esophageal complications, PV stenosis, or persistent phrenic palsy in MANIFEST-17K; general ablation risks remain. |
| Complications to watch | Vascular access complications, tamponade, stroke/TIA, pericarditis, esophageal injury, PV stenosis. | Vascular access complications, tamponade, stroke/TIA, phrenic palsy, rare esophageal injury. | Vascular access complications, tamponade, stroke/TIA, rare coronary spasm, rare hemolysis-related renal injury; device-specific learning curves matter. |
| Recurrence | Paroxysmal AF freedom from recurrence commonly lands around the same range as PFA in modern trials, depending on monitoring intensity. | Similar first-year efficacy to RF in many PVI indications. | ADVENT showed noninferiority, not superiority. Some meta-analyses suggest lower 1-year recurrence versus RF or cryo, but device mix and study design limit certainty. |
| Cost signal | Equipment costs may be lower; procedure time may be higher. | Often efficient for PVI; disposable balloon costs vary by contract. | Mixed. UK real-world data found higher median cost with PFA because device costs offset lab-time savings; a 2025 systematic review found 3 of 4 studies favored PFA by $520 to $2,387 per patient. |
Why tissue selectivity matters
PFA is aimed at the atrial myocardium, not everything nearby.
The atrial muscle cells targeted during pulmonary vein isolation appear more vulnerable to electroporation than some adjacent structures. That is the rationale behind the lower reported rates of esophageal injury, pulmonary vein narrowing, and persistent phrenic nerve injury. It does not remove procedural risks, and each PFA platform has its own waveform, catheter geometry, indications, and evidence base.
Costs, duration, and outcomes
The tradeoff is operating-room efficiency versus device cost and still-maturing durability data.
Published PFA workflows often report shorter skin-to-skin, left atrial dwell, or PVI application times. This can increase lab throughput, especially in high-volume electrophysiology programs.
Local contracts matter. One UK real-world study found median PFA cost of GBP 10,010 versus GBP 8,106 for cryoballoon and GBP 8,949 for RF. A newer systematic review found most included studies favored PFA economically, but evidence is limited.
For paroxysmal AF, pivotal studies cluster around roughly 66% to 75% composite success at 12 months depending on endpoint and monitoring. Persistent AF remains harder and often needs individualized lesion sets.
Long-term outcomes beyond 2 to 3 years, repeat-procedure durability, platform-to-platform differences, and best use outside pulmonary veins are still being defined.
Some people may be able to stop anticoagulation after ablation, but this is not automatic. Decisions usually depend on stroke-risk scoring, bleeding risk, rhythm monitoring, and cardiologist advice rather than the procedure result alone.
Companies and devices
Market share is hard to audit, so the site separates evidence from estimates.
Company-reported revenue, physician surveys, regulatory timing, and installed-base momentum do not always point to the same share number. The estimates below are directional, not investment advice or audited sales data.
Worldwide PFA programs
Electrophysiologists publicly associated with PFA publications, pivotal studies, registries, or device evidence pages
This is a research-sourced starting directory, not a credentialing statement or live booking directory. Names are included because they appear in cited PFA evidence, but patients should verify current clinic, device availability, indication, insurance, and waiting times directly.
Languages
Country language presets and full-page translation
Use the country presets for likely patient languages, or open the guide through Google Translate when the page is live on the web.
Common national languages
Source library
Primary studies and market references used for this build
ACC summary of ADVENT trial
ACC summary of PULSED AF
Nature Medicine MANIFEST-17K registry
Circulation AdmIRE pivotal trial
FDA Affera Sphere-9 approval
FDA VARIPULSE approval
Medtronic PulseSelect information
2025 systematic review of PFA cost comparisons
Heart Rhythm real-world cost and efficiency study
MedTech Dive 2026 Boston Scientific EP sales and PFA position
MedTech Dive Medtronic FY26 PFA growth
MedTech Dive J&J VARIPULSE pause and FDA recall details
Abbott PFA product information
Indirect comparison of Farawave, PulseSelect, and Varipulse
Evidence snapshot prepared May 8, 2026.